logo-loader

Full interview: Humanigen plans Phase III clinical trial for lenzilumab to treat symptoms of coronavirus patients

Published: 10:41 23 Mar 2020 EDT

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive the firm wants to carry out a Phase III clinical trial for its lenzilumab to treat cytokine storm, which can lead to acute respiratory distress syndrome (ARDS), which is associated with the current coronavirus pandemic.

Durrant says additionally, lenzilumab is available for physicians who request it through compassionate use immediately.

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

24 minutes ago